Phage susceptibility testing methods or 'phagograms': where do we stand and where should we go?

被引:1
|
作者
Kolenda, Camille [1 ,2 ]
Jourdan, Julie [1 ]
Roussel-Gaillard, Tiphaine [1 ]
Medina, Mathieu [1 ,2 ]
Laurent, Frederic [1 ,2 ]
机构
[1] Hosp Civils Lyon, Inst Agents Infect, Serv bacteriol, Lyon, France
[2] Univ Claude Bernard Lyon 1, Univ Lyon, CIRI Ctr Int Rech Infectiol, Team StaPath,Inserm,U1111,CNRS,UMR5308,ENS Lyon, Lyon, France
关键词
BACTERIOPHAGE THERAPY; EFFICACY;
D O I
10.1093/jac/dkae325
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Phage therapy is a highly promising approach to address the challenge that is presented by the global burden of antimicrobial resistance. Given the natural specificity of phages, phage susceptibility testing (PST) is a prerequisite for successful personalized therapy, allowing the selection of active phages from large and diverse collections. However, the issue of an easy-to-use and standardized technique remains. In this review, we describe the principles, advantages and drawbacks of two routinely used PST techniques: plaque and growth kinetic assays. These are labour-intensive and time-consuming methods that require automation of one or more steps, including preparation of test panels, incubation, reading and analysis of results. In addition to automation, there is an urgent need to establish a reference method to enable efficient of PST techniques selection of therapeutic phages. We discuss knowledge gaps and parameters that need to be investigated to work towards this goal.
引用
收藏
页码:2742 / 2749
页数:8
相关论文
共 50 条
  • [41] Oral immunotherapy in children with a food allergy-Where do we stand? - Review
    Pulik, Kaja
    Ruszczynski, Marek
    Krenke, Rafal
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2022, 49 (02) : 191 - 201
  • [42] Treating the primary in low burden metastatic prostate cancer Where do we stand?
    Luo, Hua-Chun
    Fu, Zhi-Chao
    Wang, Xin-Peng
    Cai, Lv-Juan
    Wang, Feng-Mei
    Yin, Qin
    Lin, Guishan
    Chen, Zhong-Hua
    Liao, Shao-Guang
    MEDICINE, 2020, 99 (51) : E23715
  • [43] Irreversible Electroporation for Locally Advanced Pancreatic Cancer Where Do We Stand in 2017?
    Tasu, Jean Pierre
    Vesselle, Guillaume
    Herpe, Guillaume
    Richer, Jean Pierre
    Boucecbi, Samy
    Velasco, Stephane
    Debeane, Bertrand
    Carretier, Michel
    Tougeron, David
    PANCREAS, 2017, 46 (03) : 283 - 287
  • [44] Intradermal Injection of Hybrid Complexes of High- and Low-Molecular-Weight Hyaluronan: Where Do We Stand and Where Are We Headed in Regenerative Medicine?
    Humzah, Dalvi
    Molina, Beatriz
    Salti, Giovanni
    Cigni, Clara
    Bellia, Gilberto
    Grimolizzi, Franco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (06)
  • [45] Serotype replacement in invasive pneumococcal disease: Where do we go from here?
    Hanage, W. P.
    JOURNAL OF INFECTIOUS DISEASES, 2007, 196 (09): : 1282 - 1284
  • [46] Influenza Vaccination of Patients Receiving Statins: Where Do We Go From Here?
    Atmar, Robert L.
    Keitel, Wendy A.
    JOURNAL OF INFECTIOUS DISEASES, 2016, 213 (08): : 1211 - 1213
  • [47] Where Do We Come From? Where Are We Going? Adverse Outcomes in Catheter Ablation for Atrial Fibrillation
    Magnani, Jared W.
    Benjamin, Emelia J.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2014, 7 (02): : 195 - 197
  • [48] Stroke prevention in heart failure and sinus rhythm: where do we go from here?
    Vaduganathan, Muthiah
    Patel, Ravi B.
    Yancy, Clyde W.
    EUROPEAN JOURNAL OF HEART FAILURE, 2016, 18 (10) : 1267 - 1269
  • [49] Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know
    Boziki, Marina Kleopatra
    Kesidou, Evangelia
    Theotokis, Paschalis
    Mentis, Alexios-Fotios A.
    Karafoulidou, Eleni
    Melnikov, Mikhail
    Sviridova, Anastasia
    Rogovski, Vladimir
    Boyko, Alexey
    Grigoriadis, Nikolaos
    BRAIN SCIENCES, 2020, 10 (04)
  • [50] Insulin-Like Growth Factor 1 Receptor Inhibitors Where Do We Come From? What Are We? Where Are We Going?
    Chmielowski, Bartosz
    CANCER, 2014, 120 (16) : 2384 - 2387